GEN vs ZBRA

GEN presents a stark contrast between strong growth fundamentals and deteriorating financial health and market sentiment. While the Piotroski F-Score of 4/9 indicates a stable but mediocre health profile, the current ratio of 0.47 and high debt-to-equity ratio of 3.63 signal significant short-term liquidity risks. Valuation is highly attractive on a forward basis (Forward P/E 6.40, PEG 0.47), but this is heavily offset by a bearish technical trend (0/100) and insider selling. The stock is currently trading near its 52-week low, suggesting the market is pricing in balance sheet fragility over growth potential.

ZBRA exhibits a stable but mediocre financial health profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided. The stock is currently trading at a significant premium to its Graham Number ($115.46) and Intrinsic Value ($57.33), suggesting a high valuation relative to current fundamentals. While the PEG ratio (0.49) and Forward P/E (11.29) indicate strong future growth expectations, these are contrasted by a severe current earnings contraction of -55.8% and bearish technical trends. Liquidity is a primary concern, evidenced by a Quick Ratio of 0.52.